Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

124.63USD
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
$124.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
148,093
52-wk High
$152.55
52-wk Low
$100.64

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $5,371.76
Shares Outstanding(Mil.): 43.56
Dividend: --
Yield (%): --

Financials

  UTHR.OQ Industry Sector
P/E (TTM): 6.98 99.04 30.20
EPS (TTM): 17.86 -- --
ROI: 33.01 3.31 12.77
ROE: 35.78 2.31 14.92

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

Apr 30 2018

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

Apr 27 2018

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage:

Mar 30 2018

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Feb 21 2018

Earnings vs. Estimates